Literature DB >> 9185595

Neutralization determinants of laboratory strains and field isolates of equine arteritis virus: identification of four neutralization sites in the amino-terminal ectodomain of the G(L) envelope glycoprotein.

U B Balasuriya1, J F Patton, P V Rossitto, P J Timoney, W H McCollum, N J MacLachlan.   

Abstract

The N-terminal hydrophilic ectodomain of the G(L) envelope glycoprotein of equine arteritis virus (EAV) contains neutralization determinants of the virus. We developed a panel of 17 neutralizing murine monoclonal antibodies (MAbs) to further characterize the neutralization determinants of EAV. Included were 6 MAbs previously raised against a laboratory strain (EAVUCD) of the original Bucyrus strain of EAV, as well as 11 additional MAbs that were raised against a neutralization-resistant variant [escape mutant (EM)] virus (EM6D10) that was derived from EAVUCD. All MAbs raised against EAVUCD and 4 of the MAbs raised against EM6D10 (2B3, 5F8, 8D4, and 10B4) reacted with the corresponding G(L) envelope glycoprotein in a Western immunoblotting assay, whereas the remaining 7 MAbs raised against EM6D10 did not react with any viral protein in the immunoblotting assay but competitively inhibited the binding of MAbs 2B3, 5F8, 8D4, and 10B4, indicating that they also recognize epitopes on the G(L) protein. A panel of 18 EM viruses raised to the MAb panel, 19 field isolates of EAV from North America and Europe, the modified-live virus vaccine (ARVAC), and 3 other laboratory strains of EAV were characterized by microneutralization assay with the panel of neutralizing MAbs and polyclonal rabbit and horse antisera. Comparative analysis of the nucleotide sequences of ORF5 and the deduced amino acid sequences of the G(L) protein of individual EM viruses and field isolates of EAV identified four distinct neutralization sites. These sites include amino acids 49 (site A), 61 (site B), 67 through 90 (site C), and 99 through 106 (site D). With the notable exception of site A, the sites were all located in the V1 variable region (amino acids 61-121) within the second half of the N-terminal hydrophilic ectodomain of the G(L) protein. Site D includes several overlapping linear epitopes which appear to interact with amino acids in the other three sites to form conformationally dependent epitopes. Amino acid substitutions within any of these four sites can alter the neutralization phenotype of individual strains of EAV.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9185595     DOI: 10.1006/viro.1997.8551

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  23 in total

1.  Monoclonal antibodies directed against conserved epitopes on the nucleocapsid protein and the major envelope glycoprotein of equine arteritis virus.

Authors:  E Weiland; S Bolz; F Weiland; W Herbst; M J Raamsman; P J Rottier; A A De Vries
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

2.  Genetic manipulation of arterivirus alternative mRNA leader-body junction sites reveals tight regulation of structural protein expression.

Authors:  A O Pasternak; A P Gultyaev; W J Spaan; E J Snijder
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Large envelope glycoprotein and nucleocapsid protein of equine arteritis virus (EAV) induce an immune response in Balb/c mice by DNA vaccination; strategy for developing a DNA-vaccine against EAV-infection.

Authors:  E Tobiasch; R Kehm; U Bahr; C A Tidona; N J Jakob; M Handermann; G Darai; M Giese
Journal:  Virus Genes       Date:  2001-03       Impact factor: 2.332

4.  Development and characterization of an infectious cDNA clone of the modified live virus vaccine strain of equine arteritis virus.

Authors:  Jianqiang Zhang; Yun Young Go; Chengjin M Huang; Barry J Meade; Zhengchun Lu; Eric J Snijder; Peter J Timoney; Udeni B R Balasuriya
Journal:  Clin Vaccine Immunol       Date:  2012-06-27

5.  Heterodimerization of the two major envelope proteins is essential for arterivirus infectivity.

Authors:  Eric J Snijder; Jessika C Dobbe; Willy J M Spaan
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

6.  Within-Host Evolution of Simian Arteriviruses in Crab-Eating Macaques.

Authors:  Louise H Moncla; Andrea M Weiler; Gabrielle Barry; Jason T Weinfurter; Jorge M Dinis; Olivia Charlier; Michael Lauck; Adam L Bailey; Victoria Wahl-Jensen; Chase W Nelson; Joshua C Johnson; Yíngyún Caì; Tony L Goldberg; David H O'Connor; Peter B Jahrling; Jens H Kuhn; Thomas C Friedrich
Journal:  J Virol       Date:  2017-01-31       Impact factor: 5.103

7.  Equine Arteritis Virus Elicits a Mucosal Antibody Response in the Reproductive Tract of Persistently Infected Stallions.

Authors:  Mariano Carossino; Bettina Wagner; Alan T Loynachan; R Frank Cook; Igor F Canisso; Lakshman Chelvarajan; Casey L Edwards; Bora Nam; John F Timoney; Peter J Timoney; Udeni B R Balasuriya
Journal:  Clin Vaccine Immunol       Date:  2017-10-05

8.  Genetic divergence with emergence of novel phenotypic variants of equine arteritis virus during persistent infection of stallions.

Authors:  J F Hedges; U B Balasuriya; P J Timoney; W H McCollum; N J MacLachlan
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

9.  Generation of a candidate live marker vaccine for equine arteritis virus by deletion of the major virus neutralization domain.

Authors:  Javier Castillo-Olivares; Roeland Wieringa; Tamás Bakonyi; Antoine A F de Vries; Nick J Davis-Poynter; Peter J M Rottier
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

10.  Development of a fluorescent-microsphere immunoassay for detection of antibodies specific to equine arteritis virus and comparison with the virus neutralization test.

Authors:  Yun Young Go; Susan J Wong; Adam J Branscum; Valerie L Demarest; Kathleen M Shuck; Mary L Vickers; Jianqiang Zhang; William H McCollum; Peter J Timoney; Udeni B R Balasuriya
Journal:  Clin Vaccine Immunol       Date:  2007-11-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.